) rallied 7.2% as it released a solid fiscal 2014 revenue
guidance along with its preliminary unaudited results for the
fourth quarter of 2013 yesterday. This provider of microfluidic
systems in growth markets is slated to release its exhaustive
fourth-quarter and fiscal 2013 results in February.
A Look at Elementary Results and Guidance
The company expects to report balanced quarterly sales across
both of its instruments and consumable segments. Instrument
revenue is expected to peg at $12 million while consumables
revenue is projected at $8.5 million, both showing solid 25.0%
and 47.8% year-over-year growth respectively. The current Zacks
Consensus Estimate for Fluidigm's total revenue remains at $19
Fluidigm is expected to exit the fourth quarter with
instrument installed base of 920 units, considerably higher than
the year ago figure of 670 units. The company also foresees
strong momentum in the single-cell genomics market that covers
almost half of the company's product revenue.
Management expects Single-cell genomics revenue to gain
twofold in 2013. For the full year 2013, the company expects to
report revenues of $71 million, an annualized growth of 35.7% as
well as a beat to the Zacks Consensus estimate of $70
We note that, expecting a strong fourth quarter, Fludigm
provided a strong outlook for full year 2014. The company
anticipates a huge 23%−28% annualized revenue growth in the
upcoming fiscal. The Zacks Consensus Estimate of $85 million,
representing a growth of 19.7% remains below the projected
Fluidigm currently carries a Zacks Rank #3 (Hold). While we
choose to remain on the sidelines regarding FLDM at present,
better-ranked medical stocks worth considering include
Natus Medical Inc.
). While Natus Medical and CryoLife sport a Zacks Rank #1 (Strong
Buy), Cepheid holds a Zacks Rank #2 (Buy).
NATUS MEDICAL (BABY): Free Stock Analysis
CEPHEID INC (CPHD): Free Stock Analysis
CRYOLIFE INC (CRY): Free Stock Analysis
FLUIDIGM CORP (FLDM): Free Stock Analysis
To read this article on Zacks.com click here.